SCHEMBL5332740

SCHEMBL5332740

CC1CCN(CC(=O)Cc2nc3ccccc3[nH]2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.54
RAB9A P51151 4/20 0.52
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 3/20 0.52
MAPK1 P28482 1/20 0.52
TRPC3 Q13507 1/20 0.51
HSD17B10 Q99714 2/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GRIN2B Q13224 2/20 0.47
GRIN1 Q05586 1/20 0.47
CHRNA7 P36544 1/20 0.47
HTT P42858 1/20 0.46
DRD4 P21917 2/20 0.46
CACNA1G O43497 1/20 0.45
HTR2B P41595 1/20 0.45
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5339354 0.88 LMNA (0.52) LMNATSHRRAB9AALDH1A1SMN1; SMN2
SCHEMBL5459362 0.88 LMNA (0.55) LMNATSHRRAB9AALDH1A1SMN1; SMN2
SCHEMBL5334025 0.86 LMNA (0.50) LMNATSHRRAB9AALDH1A1SMN1; SMN2
SCHEMBL5341963 0.85 LMNA (0.48) LMNATSHRRAB9AALDH1A1SMN1; SMN2
SCHEMBL5345348 0.79 CHRNA7 (0.73) LMNATRPC3GRIN2BGRIN1CHRNA7
SCHEMBL5342368 0.77 LMNA (0.53) LMNATSHRRAB9AALDH1A1SMN1; SMN2
SCHEMBL5337358 0.77 CHRNA7 (0.62) TRPC3GRIN2BGRIN1CHRNA7DRD4
SCHEMBL5333807 0.76 LMNA (0.51) LMNATSHRRAB9AALDH1A1SMN1; SMN2
SCHEMBL5345345 0.74 LMNA (0.49) LMNATSHRRAB9AALDH1A1SMN1; SMN2
SCHEMBL22639708 0.72 GRIN1 (0.66) ALDH1A1NPC1KDM4EGRIN2BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155795-A1 MUSCARINIC AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2007-07-05 US disclosed
US-7238713-B2 Muscarinic agonists ACADIA PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
EP-1535912-A1 Muscarinic agonists Arcadia Pharmaceuticals Inc. (US) 2005-06-01 EP disclosed
US-20050113357-A1 Muscarinic agonists ANDERSON CARL-MAGNUS A (DK) 2005-05-26 US disclosed
US-6627645-B2 Cholinergic agents ACADIA PHARMACEUTICALS, INC. 2003-09-30 US disclosed
US-20020037886-A1 Muscarinic agonists ACADIA PHARMACEUTICALS INC. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037886-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 LMNA 1956/4885TSHR 78/4885RAB9A 2681/4885
US-20070155795-A1 MUSCARINIC AGONISTS CHRM2, CHRM1, CHRM4 LMNA 1956/4885TSHR 78/4885RAB9A 2681/4885
US-20050113357-A1 Muscarinic agonists CHRM2, CHRM1, CHRM4 LMNA 1956/4885TSHR 78/4885RAB9A 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.